Post-polio Syndrome Treatment Market size is anticipated to witness lucrative growth rate during the forecast period i.e., between 2024-2036. The growth of the market can be attributed to the high prevalence of polio in underdeveloped countries, due to unavailability of polio vaccines in low-income economies. Polio was once a deadly disease, causing mass deaths and paralysis, but cases of polio have been a rarity after the development of polio vaccines, especially in developed countries. The World Health Organization (WHO) reported around 175 active polio cases in 2019. However, the prevalence of polio is high in underdeveloped countries, due to lack of efficient healthcare facilities, which is estimated to boost the market growth. Post-polio syndrome surfaces up decades after the initial infection, which is generally after the age of 30 years. The symptoms of this syndrome are severe and require continuous medication and other treatment, which is estimated to boost the growth of the post-polio syndrome treatment market. Moreover, the developing public healthcare infrastructure and high government expenditure for the development of new drugs is anticipated to significantly fuel the growth of the market.
Growth Drivers
Challenges
|
2023 |
|
|
Forecast Year |
2024–2036 |
|
Regional Scope |
|
The market is segmented by treatment into medication, physical therapy, and others, out of which, the medication segment is anticipated to hold the largest share in the post-polio syndrome treatment market over the forecast period on account of increasing use of painkillers and anticonvulsant drugs to curb the symptoms of post-polio syndrome. Drugs are given to relieve muscle and join pain and breathing difficulties, which is estimated to boost the segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Symptoms |
|
|
By Treatment |
|
On the basis of geographical analysis, the post-polio syndrome treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America is likely to account for largest revenue share by 2036, on account of presence of major pharmaceutical companies, and increasing research activities for the development of new drugs. The first polio vaccine was given in the United States in 1955, and US has been polio-free since 1979, according to the data by the Center for Disease Control and Prevention. However, the pharmaceutical industry in this region manufactures major amount of post-polio syndrome treatment drugs and medications, which is estimated to boost the market growth.
On the other hand, poor economies in Middle East and Africa and Asia Pacific are the worst affected by poliovirus, and hence, have major growth opportunities for post-polio syndrome treatment market. The market in the Middle East and Africa region is estimated to gain significant growth over the forecast period, owing to the lack of proper public healthcare system in the region, leading to rising prevalence of polio.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?